Rheumatoid Arthritis
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) Trial
TEAR is a Phase IV investigator-initiated study. The study design is a multi-center, randomized, double-blind study (2X2 factorial design).The study start date was 5-17-04. The primary objective of the trial is to evaluate the relative efficacy of two clinically important decisions using the 28 joint count (DAS28) between 48 and 102 weeks after initiation of treatment:
- To assess if it is better to intensively treat all early RA patients with multiple DMARDs or reserve this treatment only to those who do not appropriately respond to MTX monotherapy; And
- To assess if the combination therapy of MTX plus etanercept is superior to the triple combination of MTX plus SSZ plus HCQ
For more information, please visit TEAR website: www.teartrial.org
Key personnel at the Clinic Coordinating Center (CCC) include:
| Larry Moreland, MD | Principal Investigator |
| Keslie Woodsd | Program Manager |
| Sheree Carter, RN,MSN | Study Administrator |
| Candice Griffin, MPH,MBA | Quality Assurance Coordinator |
Key personnel at the Statistical and Data Management Center (SDMC) include:
| George Howard, DrPh | Co-Principal Investigator |
| Stacey Cofield , PhD | Assistant Director, SDMC |
| Tekeda Ferguson, MSPH, MPH | Project Manager/Data Manager |
| Theresa McVie, MS | Senior Statistician |
| Richard Mailhot, MS,MBA | IT Manager |
| Doug Kennedy, MS | Lead Programmer |